Current Report Filing (8-k)
January 13 2020 - 6:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 13, 2020 (January 13, 2020)
BIOSPECIFICS TECHNOLOGIES CORP.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-34236
|
|
11-3054851
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
35 Wilbur Street
Lynbrook, NY
|
|
11563
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: 516.593.7000
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, Par Value $0.001
|
|
BSTC
|
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Introductory Comment
Throughout this Current Report on Form 8-K, the terms we, us, our and
Company refer to BioSpecifics Technologies Corp.
Item 7.01
|
Regulation FD Disclosure
|
During the week of January 13, 2020, the Company will attend and partake in the J.P. Morgan 38th Annual Healthcare Conference held in San
Francisco, California (the Conference). In connection with the Conference, officers and representatives of the Company will present to investors, bankers, and other such individuals during private meetings using the presentation
materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference.
In accordance with General Instruction B.2 of
Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
BioSpecifics Technologies Corp.
|
|
|
By:
|
|
/s/ Carl A. Valenstein
|
|
|
Carl A. Valenstein
|
|
|
Corporate Secretary
|
Dated: January 13, 2020
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Jul 2024 to Aug 2024
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Aug 2023 to Aug 2024